Approvals/TGA/WINGLORE ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial

Approved

STANDARD

WINGLORE ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial

Bristol-Myers Squibb Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: f88ee3f63427cf23
Product Name: WINGLORE ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial
Artg Id: 174327
Artg Name: WINGLORE ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial
Sponsor: Bristol-Myers Squibb Australia Pty Ltd
Company Detail Path: /organization/bristol-myers-squibb-australia-pty-ltd
Artg Date: 2011-07-04
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE

Approved

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

f88ee3f63427cf23

Type

Standard